I thought you were describing Oncosil for a moment:
"There are drug companies listed on the ASX with virtually no data. Proof of concept, maybe a piss ant Phase 1 study, most likely single arm as well." Yep That's Oncosil.
"No Phase 2 study." Yep That's Oncosil.
"No Phase 3 study." TICK
"And no RCT! All single arm with very low patient data." TICK AGAIN
"No Regulatory Approvals either. None. Let that sink in. None, zero, zilch." Not quite true for Oncosil. They did get CE mark approval for Europe and will thus likely get regulatory approvals in other jurisdictions, but these are small impact approvals. How will Oncosil compete in those markets when competitors have claims to better results from phase 3 RCT trials?
"Hardly any cash in the bank either, many of these exploratory drug companies." Yep That's Oncosil. They managed to snag another $19 million of cash.
"No likely revenue either. None. Zero. Zilch." Yep. TICK AGAIN. Maybe a few sales but if those sales don't at least cover costs, then what's the point?
"CR almost a 100% certainty. Every year while they complete expensive trials." TICK. I presume Oncosil will go for FDA approval...
"No guarantees they will succeed to Phase 2 or Phase 3 either. None, Zero, Zilch." YES YESSS I agree!
(20min delay)